ID BIOMEDICAL'S CYCLING PROBE TECHNOLOGY DNA TESTS FOR DRUG-RESISTANT BACTERIA SLATED FOR LAUNCH IN 1997; POINT-OF-CARE CPT TESTS ALSO PLANNED
This article was originally published in The Gray Sheet
Executive Summary
ID Biomedical's Cycling Probe Technology DNA-based tests for detection of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) could be launched in the U.S. in 1997 following review and approval by FDA, the company predicts. Discussing the two tests Aug. 12 at the Medical Investments Northwest conference in Seattle, ID President and CEO Frank Holler said: "We expect to be able to bring [the tests] to the market next year."